IP clin	IPclin	IP clin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IP clin	IPclin	IPclin	IP clin
IP clin	IP clin	IP clin	I Pclin	I Pclin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin
IP clin	IP clin	IP clin	I Pclin	I Pclin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin
IP clin	IP clin	IP clin	I Pclin	I Pclin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin
IP clin	IPclin	IP clin	I Pclin	I Pclin	IPclin	IPclin	IPclin	I Pclin	IPclin	IPclin	IPclin	IPclin	IPclin	I Pclin	IP clin	IP clin
IP clin	IPclin	I Pclin	I Pclin	I Pclin	IPclin	IPclin	Pc S T	UDY RE	PORT	IPclin	IPclin	IPclin	IPclin	I Pclin	IP clin	IP clin
IP clin	IPclin	IPcIn	SESSM	ENT OF	THE F	RIZZ RE		ON MAC	CRO VIS SIS	UAL EF	FECTS	ON HA	IR BY II	MAGE	IP clin	IP clin
IPclin	I Pclin	I Pclin	I Pclin	I Pclin	IPclin	IPclin	I Pclin	I Pclin	I Pclin	I Pclin	IPclin	IPclin	IPclin	I Pclin	IPclin	IP clin
I Pclin	I Pclin	I Pclin	IPclin	I Pclin	I Pclin	IPclin	IPclin	I Pclin	IPclin	I Pclin	I Pclin	IPclin	IPclin	IPclin	I Pclin	IP clin
I Pclin	I Pclin	I Pclin	IPclin	I Pclin	I Pclin	IPclin	IPclin	I Pclin	IPclin	I Pclin	I Pclin	IPclin	IPclin	IPclin	I Pclin	IP clin
I Pclin	I Pclin	I Pclin	IPclin	I Pclin	I Pclin	IPclin	IPclin	I Pclin	IPclin	I Pclin	I Pclin	IPclin	IPclin	IPclin	I Pclin	IP clin
IPclin	IPclin	I Pclin	I Pclin	I Pclin	IPclin	IPclin	IPclin	I Pclin	IP clin	I Pclin	IPclin	IP clin	IP clin	I Pclin	I Pclin	IP clin
IPclin	IPclin	I Pclin	I Pclin	I Pclin	<u>IPclin</u>	IPclin	<u>IPclin</u>	I Pclin	IPclin	I Pclin	<u>IPclin</u>	IPclin			<u>IPclin</u>	IPclin
IPclin	I Pclin			I Pclin	IPclin	IPclin		2-11	N SEC		10.00				IPclin	IP clin
I Pclin	I Pclin	Spons	I Pclin	I Pclin	I Pclin	IPclin			IO IMF	IID-II-	IPdin	I Pdin	JRTAÇ	IPdin	IPclin	IP clin
IPclin	I Pclin	Addre	Pclin	I Pclin	IPclin	IPclin			ANTAF			-		ΓRO	IPclin	IP clin
I Pclin	I Pclin	LP clin		Pclin	I Pclin	IPclin	TP CIIN	D DE J. C.2015	ANEIR	O/RJ.	CEP: 2	20081-0	010 IPclin	IPclin	IPclin	IP clin
IPclin	I Pclin	I Pclin	I Pclin	I Pclin	IPclin	IPclin	LD II	TIVAT	TID III	RGII (REAL	A SMO	OTHIN	id ^P clin	IP clin	IP clin
ID It									OIL /	I VOIL (JIVEAIV	JOIVIO	OTTHI			
IPclin	IPclin	Produ	ıct Naı	ne:	IPclin	IP clin	-	LUTIO	N/AR	112111111111111111111111111111111111111	141211 74 10 1811 184	14120-1413-1413-141	1-128 /- 1-15/1-16	111111111111111111111111111111111111111	IP clin	IPclin
IPclin IPclin	IPclin IPclin	IPclin.	IPclio.	IPclin	IPclin IPclin	IPclin ate/	PO	LUTIO WDER	N/AR	GILA F	POWDI	ER - W	VHITE.	111111111111111111111111111111111111111	IPclin	IPclin IPclin
IPclin IPclin	IPclin IPclin	Batch Expira	/ Man ation [ufactu Date:		IPclin	PO 07'	DLUTIO WDER 111401 091402	N / AR R / NOT 2 / NOT	GILA F	POWDI RMED RMED	ER – W / 11/20 / 09/20	017 017	ARGIL IPclin	IPclin IPclin	IPclin IPclin
1-12-1-1-1-1-1-1-1		Batch Expira	/ Man ation [le Rec	ufactu Date: eptior	Date:	IPclin	PO 07' IP 290 IP 05/	DLUTIO WDER 111401 091402 (29/201	N / AR R / NOT 2 / NOT 5	GILA F	POWDI RMED RMED	ER – W / 11/20 / 09/20	017 017	ARGIL IPclin	IPclin IPclin	IPclin IPclin IPclin
IPclin		Batch Expira Samp Repor	/ Man ation [le Rec	ufactu Date: eptior	Date:	IPclin	PO 07' IP 290 IP 05/	DLUTIO WDER 111401 091402	N / AR R / NOT 2 / NOT 5	GILA F	POWDI RMED RMED	ER – W / 11/20 / 09/20	017 017	ARGIL IPclin	IPclin IPclin	
IPclin IPclin	IP clin	Batch Expira Samp Repor	/ Man ation I le Rec rt Emis	ufactu Date: eptior	Date:	IPclin IPclin	PO 07' 1P 290 05/ 07/	DLUTIO DWDER 111401 091402 (29/201 (14/201	N / AR R / NOT 2 / NOT 5	INFOI INFOI	POWDI RMED RMED	ER – W / 11/20 / 09/20	HITE 17 17 17 1Pclin	IPclin IPclin IPclin	IPclin IPclin IPclin	IP clin
IPclin IPclin IPclin	IPclin IPclin	Batch Expira Samp Repor	/ Man ation I le Rec rt Emis	ufactu Date: eption	Date:	IPclin IPclin IPclin	PO 07' 1P 290 1P 05/ 07/	DLUTIO WDER 111401 091402 (29/201 (14/201	N / AR NOT NOT NOT F	INFOI INFOI IPdin	POWDI RMED RMED IPdia	/ 11/20 / 09/20 / Pelin	HITE 17-lin 17-lin IP-lin IP-lin	IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin	IPclin IPclin
IPclin IPclin IPclin IPclin	IPclin IPclin IPclin	Batch Expira Samp Repor	/ Man ation D le Rec rt Emis	ufactu Date: eption ssion I	Date: Date: IPclin	IPclin IPclin IPclin IPclin	PO 1P 290 1P 05/ 07/ 1P din	0LUTIO 0WDER 111401 091402 (29/201 (14/201	N / AR NOT NOT NOT NOT	GILA FINFOI INFOI IPclin	POWDI RMED RMED IPdin IPdin IPdin	/ 11/20 / 09/20 / 09/20 / Pelin / Pelin	HITE 17-lin 17-lin 1Pelin 1Pelin 1Pelin	IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin	IPclin IPclin IPclin
IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin	Batch Expira Samp Repor	/ Man ation D le Rec rt Emis	ufacture Date: eption ssion I	IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin	PO 1P 290 1P 05/ 07/ 1P din 1P din	DLUTIO WDER 111401 091402 (29/201 (14/201 IPclin	N / AR NOT NOT NOT NOT S IPclin	INFOI INFOI IPclin IPclin IPclin	POWDI RMED RMED IPdin IPdin IPdin	IPclin IPclin IPclin	HITE 17-clin 17-clin 1P-clin 1P-clin 1P-clin 1P-clin	IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin
IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin	Batch Expira Samp Repor	/ Man ation D le Rec rt Emis	ufacture Date: seption I	IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin	PO 1P 290 1P 05/ 07/ 1P Clin 1P Clin	DLUTIO WDER 111401 091402 (29/201 (14/201 IPclin IPclin	N/AR N/NOT NOT NOT Polin IPclin IPclin	GILA FINFOI INFOI IPclin IPclin IPclin IPclin	POWDI RMED RMED IPclin IPclin IPclin	IPclin IPclin IPclin IPclin	HITE 17-clin 17-clin 1P-clin 1P-clin 1P-clin 1P-clin 1P-clin	IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin
IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin	Batch Expira Samp Repor	/ Man ation D le Rec rt Emis IPdin IPdin IPdin	ufacture Date: seption IPdin IPdi IPdi IPdin IPd	IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin	POIP 07' IP 290 IP 05/ 07/ IP Clin IP Clin IP Clin IP Clin	DLUTIO WDER 111401 091402 (29/201 (14/201 IPclin IPclin	N/AR N/NOT NOT NOT NOT Polin IPclin IPclin IPclin	GILA FINFOI INFOI IPclin IPclin IPclin IPclin IPclin	POWDI RMED RMED IPdin IPdin IPdin IPdin IPdin	Pelin IPclin IPclin IPclin IPclin	HITE 17-clin 17-clin 1P-clin 1P-clin 1P-clin 1P-clin 1P-clin 1P-clin	ARGIL IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin
IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin	Batch Expira Samp Report IPdin IPdin	/ Man ation D le Rec rt Emis IPdin IPdin IPdin IPdin	ufacturate: eption ssion I IPdin IPdin IPdin IPdin IPdin	IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IP OT' IP 290 IP 05/ OT/ IPclin IPclin IPclin IPclin IPclin	DLUTIO DWDER 111401 091402 (29/201 (14/201 IPclin IPclin IPclin	N/AR / NOT / NOT / NOT / Spelin / Spelin / IPclin / IPcli	GILA FINFOI INFOI IPclin IPclin IPclin IPclin IPclin IPclin	POWDI RMED RMED IPdin IPdin IPdin IPdin IPdin	IPclin IPclin IPclin IPclin IPclin	HITE 17-clin 17-clin 1P-clin 1P-clin 1P-clin 1P-clin 1P-clin 1P-clin 1P-clin	ARGIL IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin
IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin	Batch Expira Samp Report IPdin IPdin IPdin	/ Man ation I le Rec rt Emis IPdin IPdin IPdin IPdin IPdin	ufactu Date: eption ssion I IPdin IPdin IPdin IPdin IPdin IPdin	IPdin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IP 290 IP 05/ IP Clin	DLUTION WDER 111401 D91402 (29/201 M14/201 M14	N/AR POT NOT NOT Polin IPolin IPolin IPolin IPolin IPolin IPolin IPolin IPolin	GILA FINFOI INFOI IPclin IPcli	POWDI RMED RMED IPclin IPclin IPclin IPclin IPclin IPclin	IPclin	HITE Pelin IPelin IPelin IPelin IPelin IPelin IPelin IPelin IPelin IPelin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin
IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	Batch Expira Samp Report IPdin IPdin IPdin IPdin	/ Man ation I le Rec rt Emis IPdin IPdin IPdin IPdin IPdin	ufactu Date: eption ssion I IPdin IPdin IPdin IPdin IPdin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	PO IP 07' IP 290 IP 05/ IP Clin IP Cli	DLUTION WDER 111401 129/201 14/201 1Pclin IPclin IP	N/AR POT NOT NOT Polin IPolin IPolin IPolin IPolin IPolin IPolin IPolin IPolin	GILA FINFOI INFOI IPclin IPcli	POWDI RMED RMED IPclin IPclin IPclin IPclin IPclin IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	HITE Pelin IPelin IPelin IPelin IPelin IPelin IPelin IPelin IPelin IPelin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin	IPclin IPclin IPclin IPclin IPclin IPclin
IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	Batch Expira Samp Report IPdin IPdin IPdin IPdin	/ Man ation I le Rec rt Emis IPdin IPdin IPdin IPdin IPdin	ufactu Date: eption ssion I IPdin IPdin IPdin IPdin IPdin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin	PO IP 07' IP 290 IP 05/ IP Clin IP Cli	DLUTION WDER 111401 129/201 14/201 1Pclin IPclin IP	N/AR POT NOT NOT Polin IPolin IPolin IPolin IPolin IPolin IPolin IPolin IPolin IPolin	GILA FINFOI INFOI IPclin IPcli	POWDI RMED RMED IPclin IPclin IPclin IPclin IPclin IPclin	IPclin	HITE Pelin IPelin IPelin IPelin IPelin IPelin IPelin IPelin IPelin IPelin	ARGIL IPclin	IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin
IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	Batch Expira Samp Report IPdin IPdin IPdin IPdin	/ Man ation I le Rec rt Emis IPdin IPdin IPdin IPdin IPdin IPdin	ufactu Date: eption ssion I IPdin IPdin IPdin IPdin IPdin IPdin IPdin IPdin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin	PO IP 07' IP 290 IP 05/ IP Clin IP Cli	DLUTION WDER 111401 129/201 14/201 1Pclin IPclin IP	N/AR /NOT /NOT 5 Polin IPolin	GILA FINFOI INFOI IPclin IPcli	POWDI RMED RMED IPclin IPclin IPclin IPclin IPclin IPclin	IPclin	HITE O17 clin IPclin	IPclin	IPclin	IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin
IPclin	IPclin	Batch Expira Samp Report IPdin IPdin IPdin IPdin IPdin IPdin	/ Man ation I le Rec rt Emis IPdin IPdin IPdin IPdin IPdin IPdin IPdin IPdin IPdin	ufactu Date: eptior ssion I IPdin IPdin IPdin IPdin IPdin IPdin IPdin IPdin IPdin	IPclin	IPclin	PO IP 07' IP 290 IP 05/ O7/ IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	DLUTION WDER 111401 129/201 14/201 1Pclin IPclin IP	N/AR /NOT /NOT 5 Polin IPolin	GILA FINFOI INFOI INFOI IPclin	POWDI RMED RMED IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPclin	IPclin	VHITE 17 clin 17 clin 18 clin 19 clin 10 clin	ARGIL IPclin	IPclin	IPclin

IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin
IPclin	IPclin	IPclin	IP clin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin	IPclin
IP clin	IP clin	IPclin	I Pclin	IPclin	IP clin	IPclin	IPclin	IP clin	IPclin	IPclin	IP clin	IPclin	IP clin	IP clin	IP clin	IPclin
IPclin	IP clin	IPclin	I Pclin	IPclin	IPclin	IP clin	IP clin	IP clin	IPclin	IPclin	IP clin	I Pclin	I Pclin	IP clin	IPclin	IP clin
IPclin	IPclin	I Pclin	I Pclin	I Pclin	IPclin	IPclin	I Pclin	IPclin	I Pclin	I Pclin	IP clin	I Pclin	I Pclin	IPclin	IPclin	IP clin
I Pclin	I Pclin	I Pclin	I Pclin	I Pclin	I Pclin	I Pclin	I Pclin	INDE	X Pclin	I Pclin	I Pclin	IPclin	I Pclin	I Pclin	I Pclin	IPclin
I Pclin	IPclin	I Pclin	I Pclin	I Pclin	IPclin	I Pclin	I Pclin	I Pclin	I Pclin	IPclin	I Pclin	IPclin	I Pclin	I Pclin	IPclin	IPclin
I Pclin	IPclin	1Pclin	TRODU	CTION.	I Pclin	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	IPclin.	I.P.clin.	<u>lPclin</u>	.I.Palin.	I Pclin	.l3clin	IPclin
I Pclin	IPclin	2. OE	SJECTIV	/E	†Pelin	TPelin	Pelin	Pelin	<u> Pelin</u>	TPclin	tPclin	l Pelin	<u> Pelm</u>	†Pelin	3clin	IPclin
I Pclin	IPclin	3. ME	Produ	uct inforr	nation s	upplied	by the S	Sponsor .	I Pclin	IP clin	l Pclin	I Pclin	I Pclin	IP clin	IPclin	IPclin
I Pclin	IPclin	3.2.						-		IPclin.				I Pclin	.l3 clin	IPclin
I Pclin	IPclin	3.3.	CIIII	CIIII	CIIII	CIIII	CIIII	I CIII I	CIIII	Pelin	CIIII	CIIII	CIIII	CIIII	CIIII	IPclin
IPclin	IPclin	3.4. 3.5.	Statis	assessii tical ana	alysis	IP clin	IP clin	IP clin	IP clin	IPclin	l Pclin	l Pclin	IP clin	IP clin	IPclin	IPclin
I Pclin	IPclin		SULTS	.I.Palin	I Palin	.IPclin	<u>IPclin</u>		.I.P.clin.	IPclin.	I.P.clin.					IPclin
I Pclin	IPclin	5. CC	NCLUS FEREN	SION	IP clin	<u> TPelin</u>	1Pelin	Pelin	<u> IPalin</u>	<u> IPclin</u>	<u> Pelin</u>	<u> Pelin</u>	<u> Pelin</u>	IP clin	.18 clin	IPclin
IPclin	IPclin	I Delia	PROVA	I Delia	IP clin	IP clin	IP clin	IP clin	IP clin	IP clin	l Pclin	l Pclin	IP clin	IP clin	ledin	IP clin
I Pclin	I Pclin									I Pclin						IPclin
IPclin	IPclin	ANNEX	2 – RE	SULTS ESSES'	AND ST	TATISTI	CAL AN	IALYSIS	<u>IPclin</u>	<u> Pclin</u>	Pelin	<u> Pclin</u>	IPclin	<u>IPclin</u>	12 13	IPclin
IPclin	IPclin	IPclin	IPclin	IPclin	IPclin		IPclin	I Pclin	I Pclin	<u>IPclin</u>	I Pclin	I Pclin	I Pclin	IPclin	IPclin	IPclin
I Pclin	IPclin	IPclin	IPclin	I Pclin	IPclin	I Pclin	I Pclin	I Pclin	I Pclin	IPclin	I Pclin	IPclin	IPclin	I Pclin	IPclin	IPclin
I Pclin	IPclin	I Pclin	I Pclin	I Pclin	IPclin	I Pclin	I Pclin	I Pclin	IPclin	IPclin	I Pclin	I Pclin	I Pclin	I Pclin	IPclin	IPclin
IPclin	IPclin	IPclin	I Pclin	IPclin	IPclin	IPclin	IPclin	I Pclin	IPclin	IPclin	P clin	I Pclin	I Pclin	IPclin	IPclin	IPclin
IPclin	IPclin	IPclin	I Pclin	IPclin	IPclin	IPclin	IPclin	I Pclin	IPclin	IPclin	P clin	I Pclin	I Pclin	IPclin	IPclin	IP clin
<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	I Pclin	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	IPclin	<u>IPclin</u>	IPclin	<u>IPclin</u>	Pclin	I Pclin	I Pclin	<u>IPclin</u>	<u>IPclin</u>	IP clin
<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	I Pclin	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	I Pclin	<u>IPclin</u>	Pclin	I Pclin	I Pclin	<u>IPclin</u>	<u>IPclin</u>	I Pclin
<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	I Pclin	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	Pclin	<u>IPclin</u>	I Pclin	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>
<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u> Pclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	I Pclin	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>
<u>IPclin</u>	IPclin	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	IPclin	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u> Pclin</u>	<u>IPclin</u>	IPclin	<u>IPclin</u>	IPclin	<u>IPclin</u>
<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	I Pclin	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	IPclin	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	I Pclin	Pclin	IPclin	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>
<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	<u>IPclin</u>	I Pclin	<u>IPclin</u>	IPclin	<u>IPclin</u>	<u>IPclin</u>	IPclin
<u>IPclin</u>	I Delio	IP clin	IP clin	IP clin	IP clin	IP clin	IPclin	I Pclin	IPclin	IPclin			I Pclin	IPclin	IPclin	<u>IPclin</u>
ID II					11	100000000000000000000000000000000000000	A CONTRACTOR OF THE PARTY OF TH								100000	
	I Pclin	IPclin	IPclin	IPclin	RIZZ 24h	Pelin		sion 01	<u>IPclin</u>	<u>IPclin</u>	IPC.201	5.0243	<u>IPclin</u>	<u>IPclin</u>		IPclin
	I Pclin		IPclin	IPdi ^{FF}	IFCIII	IFCIII	Vers	sion 01		IPclin IPclin	IF CIIII	PCIIII	age 2 of	14 _{clin}		
IP clin	IPclin IPclin	IPCIPC	-017.00	IPdin	<u>IPclin</u>	<u>IPclin</u>	Vers	sion 01	<u>IPclin</u>	<u>IPclin</u>	IPclin	IPclin	14000 74101871284	***********	IPclin	IPclin
IPclin IPclin	IPclin IPclin	IPclin	-017.00 IPdin	IPclin IPclin	IPclin IPclin	IPclin IPclin	Vers IPclin	IPclin	IPclin IPclin	IPclin IPclin	IPclin IPclin	IPclin	<u>IPclin</u>	<u>IPclin</u>	IPclin IPclin	IPclin

1. INTRODUCTION

The recent evolution of digital cameras has brought a significant increase in the maximum digital resolution of the captured images, thus enabling its use for several analytical qualitative and quantitative purposes. From microscopy images' study, in which complex algorithms resolve the image, separating objects by diameters and forms, phase studies, the analysis of digital images has been applied for cosmetic assessments, for example, in make-up (KORICHI, 2002) and hair (MCMULLEN, 2003).

By using the digital photography tool it is possible to asses macroscopically the cosmetic effects visually observed on hair fibers. Therefore, it is an excellent standardized way of demonstrating the haircare products' efficacy.

The image analysis may be used to investigate several effects such as: volume, body, shape, frizz, curls definition, lengthening efficiency, straightening definition and effect, oxidative damage quantification, among others.

2. OBJECTIVE IPclin IPc

This study aimed at assessing the effects on frizz reduction, by image analysis, after application of the test product supplied by the company BRAZILIAN SECRETS HAIR INDÚSTRIA E COMÉRCIO IMPORTAÇÃO E EXPORTAÇÃO DE COSMÉTICOS LTDA..

IPa3a METHODOLOGYa IPalia IPalia IPalia IPalia IPalia IPalia

3.1. Product information supplied by the Sponsor

Sample Code	Product Name	Tress (code)
Polin IPolin Control IPolin IPolin	P STANDARD SHAMPOO	Point $P \in C_1, C_2, C_3$
Pelin IPelin IPe	ACTIVATOR - ARGIL CREAM SMOOTHING SOLUTION / ARGILA POWDER – WHITE ARGIL POWDER	Pelin IPelin IPelin I Pelin IPelin IPelin I

One sample of the product will be kept at IPclin[®] during 2 months after the emission of the Study Report.

3.2. Tresses Preparation

6 virgin dark curly hair tresses were prepared, each one weighting 3 g and measuring 25 cm. The tresses were divided into 2 groups of 3 tresses for product application, according to item 3.1.

Pall The product application procedure is described on ANNEX 1. | Pall Pall Pall Pall Pall

FRIZZ 24h	IPC.2015.0243
Pelin Pelin Pelin Pelin Pelin Pelin Pelin	<u> 18ain 18ain 18ain 18ain 18ain 18ain 1</u>
Vargion 01	

IPC-017.00 IPclin IPcli

After standardization and corresponding treatments, the tresses were kept at standardized environment at 85 ± 5% of relative humidity and 22 ± 2°C during the 24 hours of assay's execution in a specific equipment, as described on the topic "digital images acquisition".

IPclin IPclin 1Pclin IPclin IP

The tresses were positioned for photography in the internally developed equipment, composed by background illumination and chamber for environmental conditions' control, as represented on **Figure 1**.



Figure 1. Specific support for standardization of light, distance and environmental condition for image capture of hair tresses

Pello IP The digital camera is fixed in a tripod with constant height and distance in relation to the tresses.

The background illumination aims at highlighting the contrast of the hair fibers.

The equipment also allows the rotation of the tresses for image acquisition at previously established angles. For this study the adopted angles were 0°, 90°, 180° and 270°. The images at different angles on the same experimental time aim to compensate non uniform variations on the shape of the tress. The values of the parameters, when presented per tress, correspond to the average of the values obtained on these four angles.

Images were registered on the initial time (t0 – baseline) and after 24 hours of products application (t24h).

FRIZZ 24h	IPC.2015.0243	alio IDalio II
CIIII IFCIII IFCIII	ILCON ILCON ILCON ILCON ILCON	


Persion 01

IPC-017.00 IPclin IPclin

3.4. Frizz assessment IPclin I

Point Point Point The image of the tress is submitted to filter and background flatness to improve contrast. Many operations based on erosion and dilation detect the loose hair fibers from the image and the area occupied by them.

> Figure 2 illustrates an image from a tress on the original format and after filtering for frizz measurement. IPclin IPc



The image treatment evidences three parameters based on the occupied area:

- a) The blank region on the center of the image corresponds to the main tress body. The main tress body is composed by more adhered fibers and remains darker when contrasted with the enlightened background.
- b) The black region involving the tress body corresponds to the frizz area. The analysis algorithm detects the loose fibers of the tress and fulfills the whole area affected by those fibers with a dark color.
- c) Tress volume: is the sum of the white and black regions. The higher this value, the higher will be the perceived tress volume.

Polin IPolin	IPclin IPclin IPclin IPclin II	clin IPclin IPclin IPclin IPclin IPclin IPclin IPclin IPc	
Polin IPolin	FRIZZ 24h	IPC.2015.0243	
Pclin IPclin	IPC-017.00 IPclin IPclin IPclin IF	Version 01 Polin IPolin	

3.5. Statistical analysis Polin IPolin IPoli


SPSS 17.0 was used for the statistical analysis. A variance analysis comparing the values of the treated tresses with the same parameters for the control tresses (standard shampoo) was performed for each time separately. The alpha value of 5% was adopted as limit to declare difference between groups

IPc4: RESULTS:n IPclin IPclin

Frizz results and statistical analysis are on ANNEX 2. The obtained images are on ANNEX 3.

Graph 1 shows the results' variation (delta) for frizz area with time. The delta is calculated for each treatment as the frizz difference between the tress' frizz on the final and initial times. Positive delta values indicate frizz increase with time. Therefore, negative delta values indicate frizz reduction.

We can observe by the graph that the delta value was positive for both treated and control tresses. However, the delta value was lower for the treated tresses compared with the control. This evidences the treatment efficacy.




Graph 1. Frizz variation values' results per treatment per time

Graph 2 presents the absolute frizz values (frizz area) for the treated and control tresses at different times. We observed that the treated tresses obtained lower frizz values compared to the control tresses after 24 hours. This result demonstrates the treatment's efficacy in frizz control.

FRIZZ 24h IPC.2015.0243 Version 01 IPC-017.00

Page 6 of 14



Graph 2. Absolute frizz values per treatment per time

The statistical analysis revealed that:

FRIZZ 24h

- There was no significant difference between the frizz values obtained for the treated and control tresses on t0h.
 - There was statistically significant difference between the frizz values obtained for the treated and control tresses on t24h.

When comparing the frizz alteration percentage with time between treatments we noted that: the control increased frizz by 136% after 24 hours; the treated tresses obtained an increase of 100% after 24 hours. Therefore, when comparing the treatments we could verify that the combined use of the products ACTIVATOR - ARGIL CREAM SMOOTHING SOLUTION / ARGILA POWDER – WHITE ARGIL POWDER promoted frizz reduction of 36% after 24 hours.

Pclin IPclin IPc

Pclin IPclin IPc

IPC.2015.0243

5. CONCLUSION

In the study entitled "ASSESSMENT OF THE FRIZZ REDUCTION MACRO VISUAL EFFECTS ON HAIR BY IMAGE ANALYSIS", referring to the products ACTIVATOR - ARGIL CREAM SMOOTHING SOLUTION / ARGILA POWDER - WHITE ARGIL POWDER, code IPC.2015.0243, sent by the Sponsor BRAZILIAN SECRETS HAIR INDÚSTRIA E COMÉRCIO IMPORTAÇÃO E EXPORTAÇÃO DE COSMÉTICOS LTDA., we can conclude that:

The treatment with the products ACTIVATOR - ARGIL CREAM SMOOTHING SOLUTION / ARGILA POWDER - WHITE ARGIL POWDER demonstrated statistically significant efficacy (p < 0,05) in frizz improvement for until 24 hours in relation to the control treatment (standard shampoo).

The treatment with the products ACTIVATOR - ARGIL CREAM SMOOTHING SOLUTION / ARGILA POWDER - WHITE ARGIL POWDER promoted frizz improvement of 36% after 24 hours compared with the control treatment (standard shampoo).

This report is intended solely for the Agência Nacional de Vigilância Sanitária do Ministério da and the internal company use BRAZILIAN SECRETS HAIR INDÚSTRIA E COMÉRCIO IMPORTAÇÃO E EXPORTAÇÃO DE COSMÉTICOS LTDA.. No information in this report may be disclosed in any communication media without the written permission of the author.


NOTE 1: The result is referred to the received sample. | Polin | Polin | Polin |

NOTE 2: The sampling was performed by the study sponsor.


NOTE 3: The partial reproduction of this Study Report is prohibited.

FRIZZ 24h IPC.2015.0243

Version 01
Pelin IPelin IPelin



IPclin	IPclin	ı İPclin İPclin İPclin İPclin İPclin İPclin İPclin İPclin İPclin İPclin İPclin İPclin İPclin İPclin İPclin İP	clin									
IPclin	IPclin	IPclin IP	clin									
IPclin	IPclin	IPclin IP	clin									
IPclin	IPclin	IPclin IP	clin									
IPclin	IPclin	IPclin IP										
IPclin	IPclin											
IPclin	IPclin	IPclin IP	clin									
IPclin	IPclin	CUIDADOS ANTES E DEPOIS DE REALIZAR O PROCEDIMENTO ARGILA: A primeira lavagem pode ser										
IPclin	IPclin	rea-lizada de imediato, após o tratamento concluído. / Que tipo de manutenção deve ser usada? Recomendamos a linha de manutenção Argila Maintenance, que garante a saúde dos fios e a durabilidade dos resultados: Smooth										
IPclin	IPclin	Prolonging Shampoo, e Smooth extending masque e MuruMuru Sealer. / Quando usar secador ou prancha aplique o Murumuru sealer, / Após realizar o tratamento Argila o cabelo pode sofrer um desbotamento de até 1 tom. Pode ser	clin									
IPclin	IPclin		clin									
IP clin	IPclin		clin									
IP clin	IPclin	com bases de hidróxidos de guanidina ou sódio, tioglicolato de arnônia, etanolamina, permanente regular, permanente afro, colorações permanentes, semi permanentes ou tonalizantes, porém EXISTEM RESTRIÇÕES no momento da	clin									
IP clin	IP clin	aplicação com outras químicas. Devendo sempre avaliar a porosidade e a resistência do cabelo antes de realizar qualquer procedimento químico no cabelo. / Não deve ser utilizado sobre tinturas à base de metais pesados, hennas	clin									
IP clin	IP clin		clin									
IP clin	IP clin		clin									
IP clin	IP clin		clin									
IP clin	IP clin		clin									
IP clin	IPclin	3) O procedimento é indicado para qualquer tipo de cabelo? Sim. Devendo sempre avallar as condições do cabelo, sua porosidade e elasticidade. 4) Sabendo que para cada tipo de cabelo, o efeito liso poderá apresentar um resultado in IP	clin									
IP clin	IPclin	diferente. Os cabelos crespos (bem espiral) tem um número menor de cutículas (escamas) e o produto acaba fixando	clin									
IP clin	IP clin	produtos são totalmente livres de formol de acordo com testes comprobatórios 6.) Como e com que frequência deve	clin									
IP clin	IPclin	o padrão de liso e a reducão de volume atingida no comprimento e pontas Caso o resultado não esteja satisfatório	clin									
11211111111111111111111	IPclin	conforme o tipo de cabelo 7.) Areila pode ser aplicada em sestantes crianças e adolescentes? Não recomendamos o	clin									
	IP clin		clin									
1123 T 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	IP clin	queda de cabelos 3) Alimentos saudáveis são fundamentais para manter os cabelos perfeitos A) Realizar	clin									
1-120-1-1-1-1-1-1-1	IP clin	no salão com a linha de manutenção 6) Mudar de shampoo periodicamente, para o cabelo não ficar acostumado	clin									
1-128 1-11-11-11-11	IP clin	com o cabelo liso evistem outras coções para inquar 8 Tosoura has pontas mortas a cada 10 semanas recomenda-	clin									
1123 T 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	IPclin	plensidade do coura cabelludo. Além disso, a água quente aumenta a quantidade de frizz 10) Drendedores de cabello	clin									
	IPclin	malhada	clin									
		ı IPclin										
1-128 / 8 1 (1818) 84	1-1287-1-1297-1-84	ı IPclin										
IPclin.	1-12-11-1-11-1-1-1-1	FRI77 2/h IPC 2015 02/3										
		Version 01 Pelin IPcli										
***********	1 - 12 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	ı IPclin	. 1. 1. 1. 1. 1.									
1-120-1-1-1-1-1-1	1-12-11-1-11-1-1-1-1	ı IPclin										
		IPclin IP										



IPclin IP

ΑN	O١	VΑ
----	----	----

AROVA										
-	Sum of Squares	df	Mean Square	F	Sig.	In IPalin IPalin				
Between Groups	11,523	1	11,523	1,279	,270	in IPclin IPclin				
Within Groups	198,188	22	9,009			in IPclin IPclin				
Total	209,711	23				in IPclin IPclin				
Between Groups	497,042	1	497,042	13,599	,001					
Within Groups	804,075	22	36,549			in IPclin IPclin				
Total	1301,117	23				in IPclin IPclin				
	Within Groups Total Between Groups Within Groups	Sum of Squares Between Groups 11,523 Within Groups 198,188 Total 209,711 Between Groups 497,042 Within Groups 804,075	Sum of Squares df Between Groups 11,523 1 Within Groups 198,188 22 Total 209,711 23 Between Groups 497,042 1 Within Groups 804,075 22	Sum of Squares df Mean Square Between Groups 11,523 1 11,523 Within Groups 198,188 22 9,009 Total 209,711 23 Between Groups 497,042 1 497,042 Within Groups 804,075 22 36,549	Sum of Squares df Mean Square F Between Groups 11,523 1 11,523 1,279 Within Groups 198,188 22 9,009 9,009 1 Total 209,711 23 23 23 23 23 24 1 497,042 1 13,599 36,549 36,5	Sum of Squares df Mean Square F Sig. Between Groups 11,523 1 11,523 1,279 ,270 Within Groups 198,188 22 9,009 9,009 1 1 209,711 23 1 209,711 23 1 497,042 1 497,042 13,599 ,001 36,549 1 497,042 1 36,549 1 497,042 1 <t< td=""></t<>				

IPclin IPclin IPcl

IPclin IPclin IPclin IPc

IPclin IPclin IPclin IPclin

Frizz Resu	in IPclin IPclin IPclin				
Tuess / Amela	Control	Control Tresses		Tresses	
Tress / Angle	t0	t24h	t0	t24h	in IPclin IPclin IPclin
M1a	16.73	40.96	15.50	31.73	lin IPclin IPclin IPclin
M1b	18.36	46.25	15.24	35.22	in IPclin IPclin IPclin
M1c	17.37	45.81	16.78	30.92	In IPain IPain IPain
M1d	17.94	43.52	14.89	35.15	lin IPclin IPclin IPclin
M2a	16.80	47,04	11.64	38.44	in IPclin IPclin IPclin
M2b	15.26	48.31	12.45	39.12	111, B2 112, B1 111, B
M2c	17.74	49.92	13.21	39.85	lin IPclin IPclin IPclin
M2d	17.03	48.55	12.76	40.02	in IPclin IPclin IPclin
M3a	18.90	37.76	22.24	28.03	111 A 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M3b	19.26	35.57	20.36	27.63	lin IPclin IPclin IPclin
M3c	20.44	33.52	22.14	25.39	lin IPclin IPclin IPclin
M3d	19.57	30.25	21.56	26.74	lio IDalio IDalio IDalio
Average	17.9	42.3	16.6	33.2	in IPclin IPclin IPclin

% variation with time	236%	200%
% variation of the treated compared	d with control	-36%

Delta	24.4	16.6	lio IDclio	IPclio IPclio	

IPclin IPcl	in IPclin	IPclin IPclin	Pclin II	Pclin IPclin	IPclin	IPclin IP	clin IPc	lin IPclin	IPclin	IPclin	IPclin	IPclin
IDalia IDal	io ID-lio	ID-lin ID-li	RIZZ 24h	Dalia I Dalia	ID-li-	ID-I:- ID	IPC	2015.0243	ID-lin	ID-lin	LDelio	IDelio
IFCIII IFCI	III IFCIIII	IFCIII IFCII	I I FCIII II	CIII I CIII	I I F CIII I	I CIII I I	CIIII IFC		I F CIII I	FCIIII	I F CIII I	I F CIII I

Version 01 IPclin IP Page 12 of 14

